Literature DB >> 8263870

Relationship between C-reactive protein levels and intraamniotic infection in women with preterm labor.

M Mazor1, A Kassis, S Horowitz, A Wiznitzer, O Kuperman, C Meril, M Glezerman.   

Abstract

The purpose of this study was to determine the relationship between C-reactive protein (CRP) levels and intraamniotic infection in 48 women presenting with preterm labor and intact membranes. Blood samples for CRP tests were obtained immediately before the performance of transabdominal amniocentesis. The prevalence of amniotic fluid cultures positive for organisms was 14.6%. In 16 women (33.3%) positive CRP levels were obtained. There were no significant differences in the prematurity rate or the prevalence of microbial invasion of the amniotic cavity between women with positive CRP levels and women with negative levels. The sensitivity, specificity, and positive and negative predictive values for the detection of amniotic infection were 71.5%, 73.2%, 31.3% and 93.8%, respectively. Based on these results, we suggest that in women with preterm labor and negative CRP levels, routine amniocentesis may not be essential to the initial workup.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8263870

Source DB:  PubMed          Journal:  J Reprod Med        ISSN: 0024-7758            Impact factor:   0.142


  13 in total

1.  Antibiotic administration can eradicate intra-amniotic infection or intra-amniotic inflammation in a subset of patients with preterm labor and intact membranes.

Authors:  Bo Hyun Yoon; Roberto Romero; Jee Yoon Park; Kyung Joon Oh; JoonHo Lee; Agustin Conde-Agudelo; Joon-Seok Hong
Journal:  Am J Obstet Gynecol       Date:  2019-03-27       Impact factor: 8.661

2.  Interleukin-19 in fetal systemic inflammation.

Authors:  Zeynep Alpay Savasan; Tinnakorn Chaiworapongsa; Roberto Romero; Youssef Hussein; Juan Pedro Kusanovic; Yi Xu; Zhong Dong; Chong Jai Kim; Sonia S Hassan
Journal:  J Matern Fetal Neonatal Med       Date:  2012-04-03

3.  Level of C - reactive protein as an indicator for prognosis of premature uterine contractions.

Authors:  Bayar M Najat Nakishbandy; Sabat A M Barawi
Journal:  J Prenat Med       Date:  2014 Jan-Mar

4.  Maternal serum C-reactive protein level does not change significantly after fetal reduction: it could be used as an indicator of chorioamnionitis.

Authors:  S U Chen; T M Ko; H L Hwa; P J Lu; H N Ho; Y S Yang
Journal:  J Assist Reprod Genet       Date:  2001-06       Impact factor: 3.412

5.  Plasma C-reactive protein in early pregnancy and preterm delivery.

Authors:  Waranuch Pitiphat; Matthew W Gillman; Kaumudi J Joshipura; Paige L Williams; Chester W Douglass; Janet W Rich-Edwards
Journal:  Am J Epidemiol       Date:  2005-10-19       Impact factor: 4.897

6.  Maternal serum C-reactive protein concentrations in early pregnancy and subsequent risk of preterm delivery.

Authors:  Vitool Lohsoonthorn; Chunfang Qiu; Michelle A Williams
Journal:  Clin Biochem       Date:  2007-01-05       Impact factor: 3.281

7.  Relationship between maternal serum C-reactive protein, funisitis and early-onset neonatal sepsis.

Authors:  Sung Youn Lee; Kyo Hoon Park; Eun Ha Jeong; Kyung Joon Oh; Aeli Ryu; Kyoung Un Park
Journal:  J Korean Med Sci       Date:  2012-05-26       Impact factor: 2.153

8.  Usefulness of marking alkaline phosphatase and C-reactive protein in monitoring the risk of preterm delivery.

Authors:  Hubert Huras; Piotr Ossowski; Robert Jach; Alfred Reron
Journal:  Med Sci Monit       Date:  2011-11

9.  A fetal and an intra-amniotic inflammatory response is more severe in preterm labor than in preterm PROM in the context of funisitis: unexpected observation in human gestations.

Authors:  Chan-Wook Park; Bo Hyun Yoon; Joong Shin Park; Jong Kwan Jun
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

10.  Maternal serum interleukin 6 and 8 and C-reactive protein in predicting the tocolytic therapy in preterm labor.

Authors:  Zahra Shahshahan; Leila Hashemi; Ousha Rasouli
Journal:  J Res Med Sci       Date:  2014-06       Impact factor: 1.852

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.